Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Bucknelly21on Feb 26, 2020 1:18pm

63 Views

Post# 30736366

RE:RE:RE:RE:RE:RBC Cuts Price Target on Theratechnologies to $3 From $3.50

Then they don't have the right skills to take this company any further, plain and simple. And if you think they do you will be disappointed when you want to sell your position. I've had enough of the reluctance to change. It's costing everyone dearly except them when they get compensated for literally providing no value to current shareholders

Bullboard Posts

Canadian government to fund Electric Royalties portfolio property